Skip to main content
Top
Published in: Supportive Care in Cancer 3/2020

Open Access 01-03-2020 | Care | Original Article

Palliative care assessment of dry mouth: what matters most to patients with advanced disease?

Authors: Michelle Fleming, Cheryl L. Craigs, Michael I. Bennett

Published in: Supportive Care in Cancer | Issue 3/2020

Login to get access

Abstract

Purpose

Dry mouth is a highly prevalent and significant symptom in patients with advanced progressive diseases. It is a poorly understood area of research, and currently, there is no standardised outcome measure or assessment tool for dry mouth.

Methods

To assess responses to self-reported dry mouth questions, the impact of dry mouth, methods used to reduce symptoms and relevance of the questionnaire. A cross-sectional multisite study of 135 patients with advanced progressive disease experiencing dry mouth. Participants were located in the inpatient, day care, outpatient or community setting.

Results

The majority (84.4%) of patients rated their dry mouth as moderate or severe using the verbal rating scale (VRS). Seventy-five percent (74.7%) had a numeric rating scale (NRS) score of 6 or more for dry mouth severity. Patients reported that dry mouth interfered most with talking and was the most important function to assess (median score 6 out of 10) followed by eating (median 5) and taste (median 5). Taking sips of drink was the most common and most effective self-management strategy. Over half of patients (54.6%) also reported impact on swallow and sleep and associated dryness of lips, throat and nasal passages.

Conclusions

This study highlights the severity of dry mouth in advanced disease. Important factors when assessing patients with dry mouth should include the functional impact on day-to-day activities including talking, dysphagia and sleep. Simple considerations for patients include provision of drinks and reviewing medications. This study could be used to develop a standardised assessment tool for dry mouth to use in clinical practice.
Literature
1.
go back to reference Nederfors T, Isaksson R, Mörnstad H, Dahlof C (1997) Prevalence of perceived symptoms of dry mouth in an adult Swedish population-relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 25(3):211–216CrossRef Nederfors T, Isaksson R, Mörnstad H, Dahlof C (1997) Prevalence of perceived symptoms of dry mouth in an adult Swedish population-relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 25(3):211–216CrossRef
2.
go back to reference Jobbins J, Bagg J, Finlay IG, Addy M, Newcombe RG (1992) Oral and dental disease in terminally ill cancer patients. Brit Med J 304(6842):1612CrossRef Jobbins J, Bagg J, Finlay IG, Addy M, Newcombe RG (1992) Oral and dental disease in terminally ill cancer patients. Brit Med J 304(6842):1612CrossRef
3.
go back to reference Senn HJ (1997) Orphan topics in supportive care: how about xerostomia? Support Care Cancer 5(4):261–262CrossRef Senn HJ (1997) Orphan topics in supportive care: how about xerostomia? Support Care Cancer 5(4):261–262CrossRef
4.
go back to reference Davies AN, Broadley K, Beighton D (2001) Xerostomia in patients with advanced cancer. J Pain Symptom Manag 22(4):820–825CrossRef Davies AN, Broadley K, Beighton D (2001) Xerostomia in patients with advanced cancer. J Pain Symptom Manag 22(4):820–825CrossRef
5.
go back to reference Miletich I (2010) Introduction to salivary glands: structure, function and embryonic development. In: Tucker AS, Miletich I (eds) Salivary glands. Development, adaptations and disease, Front Oral Biol. Karger, Basal, pp 1–20 Miletich I (2010) Introduction to salivary glands: structure, function and embryonic development. In: Tucker AS, Miletich I (eds) Salivary glands. Development, adaptations and disease, Front Oral Biol. Karger, Basal, pp 1–20
6.
go back to reference Whelton H (2012) Introduction: the anatomy and physiology of salivary glands. In: Edgar WM, Mullane DM (eds) Saliva and oral health, 4th edn. Stephen Hancocks limited, pp 1–16 Whelton H (2012) Introduction: the anatomy and physiology of salivary glands. In: Edgar WM, Mullane DM (eds) Saliva and oral health, 4th edn. Stephen Hancocks limited, pp 1–16
7.
go back to reference Van’t Hof W, Veerman ECI, Nieuw Amerongen AV, Ligtenberg AJM (2014) Antimicrobial defence systems in saliva. In: Ligtenberg AJM, Veerman ECI (eds) Saliva: secretion and functions, Monogr Oral Sci. Karger, Basal, pp 40–51 Van’t Hof W, Veerman ECI, Nieuw Amerongen AV, Ligtenberg AJM (2014) Antimicrobial defence systems in saliva. In: Ligtenberg AJM, Veerman ECI (eds) Saliva: secretion and functions, Monogr Oral Sci. Karger, Basal, pp 40–51
8.
go back to reference Twycross R, Wilcock A, Toller C (2009) (eds) Symptom management in advanced cancer, 4th edn. Palliativedrugs.com Ltd, pp 62–5 Twycross R, Wilcock A, Toller C (2009) (eds) Symptom management in advanced cancer, 4th edn. Palliativedrugs.com Ltd, pp 62–5
9.
go back to reference Rydholm M, Strang P (2002) Physical and psychosocial impact of xerostomia in palliative cancer care: a qualitative interview study. Int J Palliat Nurs 8(7):318–332CrossRef Rydholm M, Strang P (2002) Physical and psychosocial impact of xerostomia in palliative cancer care: a qualitative interview study. Int J Palliat Nurs 8(7):318–332CrossRef
10.
go back to reference Sreebny LM, Valdini A (1988) Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458CrossRef Sreebny LM, Valdini A (1988) Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458CrossRef
11.
go back to reference Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP (2009) Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med 23(3):257–265CrossRef Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP (2009) Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med 23(3):257–265CrossRef
12.
go back to reference Sheehan C, Clark K, Lam L, Chye R (2011) A retrospective analysis of primary diagnosis, comorbidities, anticholinergic load, and other factors on treatment for noisy respiratory secretions at the end of life. Palliat Med 14(11):1211–1216CrossRef Sheehan C, Clark K, Lam L, Chye R (2011) A retrospective analysis of primary diagnosis, comorbidities, anticholinergic load, and other factors on treatment for noisy respiratory secretions at the end of life. Palliat Med 14(11):1211–1216CrossRef
13.
go back to reference Hanchanale S, Adkinson L, Daniel S, Fleming M, Oxberry SG (2015) Systematic literature review: xerostomia in advanced cancer patients. Support Care Cancer 23(3):881–888CrossRef Hanchanale S, Adkinson L, Daniel S, Fleming M, Oxberry SG (2015) Systematic literature review: xerostomia in advanced cancer patients. Support Care Cancer 23(3):881–888CrossRef
14.
go back to reference Sweeney MP, Bagg J, Baxter WP, Aitchison TC (1997) Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients. Palliat Med 11(3):225–232CrossRef Sweeney MP, Bagg J, Baxter WP, Aitchison TC (1997) Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients. Palliat Med 11(3):225–232CrossRef
15.
go back to reference Davies AN, Daniels C, Pugh R, Sharma K (1998) A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat Med 12(2):105–111CrossRef Davies AN, Daniels C, Pugh R, Sharma K (1998) A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat Med 12(2):105–111CrossRef
16.
go back to reference Davies AN (2000) A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliat Med 14(3):197–203CrossRef Davies AN (2000) A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliat Med 14(3):197–203CrossRef
17.
go back to reference Mercadante S, Calderone L, Villari P, Serretta R, Sapio M, Casuccio A, Fulfaro F (2000) The use of pilocarpine in opioid-induced xerostomia. Palliat Med 14(6):529–531CrossRef Mercadante S, Calderone L, Villari P, Serretta R, Sapio M, Casuccio A, Fulfaro F (2000) The use of pilocarpine in opioid-induced xerostomia. Palliat Med 14(6):529–531CrossRef
18.
go back to reference Nikles J, Mitchell GK, Hardy J, Agar M, Senior H, Carmont SA, Schluter PJ, Good P, Vora R, Currow D (2015) Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: a feasibility study. Palliat Med 29(10):967–974CrossRef Nikles J, Mitchell GK, Hardy J, Agar M, Senior H, Carmont SA, Schluter PJ, Good P, Vora R, Currow D (2015) Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: a feasibility study. Palliat Med 29(10):967–974CrossRef
19.
go back to reference Mahoney FI, Barthel D (1965) Functional evaluation: the Barthel Index. Md State Med J 14:56–61 Mahoney FI, Barthel D (1965) Functional evaluation: the Barthel Index. Md State Med J 14:56–61
20.
go back to reference Bennett M, Ryall N (2000) Using the modified Barthel index to estimate survival in cancer patients in hospice: observational study. BMJ 321(7273):1381–1382CrossRef Bennett M, Ryall N (2000) Using the modified Barthel index to estimate survival in cancer patients in hospice: observational study. BMJ 321(7273):1381–1382CrossRef
21.
go back to reference Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky performance status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Palliat Care 4:7CrossRef Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky performance status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Palliat Care 4:7CrossRef
22.
go back to reference Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR (2006) The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 46(12):1481–1486CrossRef Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR (2006) The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 46(12):1481–1486CrossRef
25.
go back to reference Furness S, Worthington HV, Bryan G, Birchenough S, Mcmillan R (2011) Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev Furness S, Worthington HV, Bryan G, Birchenough S, Mcmillan R (2011) Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev
26.
go back to reference Kim JO, Kim NC (2014) Effects of 4% hypertonic saline solution mouthwash on oral health of elders in long term care facilities. J Korean Acad Nurs Feb 44(1):13–20CrossRef Kim JO, Kim NC (2014) Effects of 4% hypertonic saline solution mouthwash on oral health of elders in long term care facilities. J Korean Acad Nurs Feb 44(1):13–20CrossRef
28.
go back to reference Atkinson JC, Shiroky JB, Macynski A, Fox PC (1989) Effects of furosemide on the oral cavity. Gerodontology 8(1):23–26CrossRef Atkinson JC, Shiroky JB, Macynski A, Fox PC (1989) Effects of furosemide on the oral cavity. Gerodontology 8(1):23–26CrossRef
29.
go back to reference Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kassa S (2011) Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manag 41(6):1073–1093CrossRef Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kassa S (2011) Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manag 41(6):1073–1093CrossRef
30.
go back to reference Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, Muscoplat CC, Gallagher SC (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329(6):390–395CrossRef Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, Muscoplat CC, Gallagher SC (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329(6):390–395CrossRef
31.
go back to reference Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, Jackson W, Delapenha RA, Shiroky J, Baum BJ (1991) Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151(6):1149–1152CrossRef Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, Jackson W, Delapenha RA, Shiroky J, Baum BJ (1991) Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151(6):1149–1152CrossRef
Metadata
Title
Palliative care assessment of dry mouth: what matters most to patients with advanced disease?
Authors
Michelle Fleming
Cheryl L. Craigs
Michael I. Bennett
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Keyword
Care
Published in
Supportive Care in Cancer / Issue 3/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04908-9

Other articles of this Issue 3/2020

Supportive Care in Cancer 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine